檢索結果 - Vivian Laquer

  • Showing 1 - 10 results of 10
Refine Results
  1. 1
    Long-Term Safety and Efficacy of Tralokinumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years

    Long-Term Safety and Efficacy of Tralokinumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years 由 Andrew Blauvelt, Vivian Laquer, Richard Langley, Chih-ho Hong, Christian Bjerregård Øland, Le Gjerum, Ann-Marie Tindberg, Kristian Reich

    出版 2025
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    Pharmacokinetics, Safety, Efficacy, and Biomarker Profiles During Nemolizumab Treatment of Atopic Dermatitis in Adolescents

    Pharmacokinetics, Safety, Efficacy, and Biomarker Profiles During Nemolizumab Treatment of Atopic Dermatitis in Adolescents 由 Robert Sidbury, Sady Alpizar, Vivian Laquer, Sunil Dhawan, William Abramovits, Luca Loprete, Jayendar Kumar Krishnaswamy, Faiz Ahmad, Zarif K. Jabbar‐Lopez, Christophe Piketty

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    Importance of treating acne sequelae in skin of color: 6‐month phase <scp>IV</scp> study of trifarotene with an appropriate skincare routine including <scp>UV</scp> protection in acne‐induced post‐inflammatory hyperpigmentation

    Importance of treating acne sequelae in skin of color: 6‐month phase <scp>IV</scp> study of trifarotene with an appropriate skincare routine including <scp>UV</scp> protection in a... 由 Andrew Alexis, J.Q. Del Rosso, Seth Forman, Antonio Martorell, John Browning, Vivian Laquer, Seemal R. Desai, Jean Philippe York, Rajeev Chavda, Sunil Dhawan, Angela Moore, Linda Stein‐Gold

    出版 2024
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)

    Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the... 由 Andrew Blauvelt, Barry Ladizinski, Vimal H. Prajapati, Vivian Laquer, Alison Fischer, Samantha Eisman, Xiaofei Hu, Tianshuang Wu, Brian Calimlim, Blair Kaplan, Yingyi Liu, Henrique D. Teixeira, John Liu, Kilian Eyerich

    出版 2023
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis

    Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis 由 April W. Armstrong, Melinda Gooderham, Charles Lynde, Catherine Maari, Seth Forman, Lawrence Green, Vivian Laquer, Xinyan Zhang, Nathalie Franchimont, Esha Gangolli, Jessamyn Blau, Yiwei Zhao, Wenwen Zhang, Bhaskar Srivastava, Graham Heap, Kim Papp

    出版 2024
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials

    Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials 由 Linda Stein Gold, Diamant Thaçi, Jacob P. Thyssen, Melinda Gooderham, Vivian Laquer, Angela Moore, Chitra R Natalie, Fangyi Zhao, Eric Meskimen, Hany Elmaraghy, Sonia Montmayeur, Gaia Gallo, Gemma Jiménez-Guerra, Marjolein de Bruin‐Weller

    出版 2023
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial

    Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial 由 Andrew Blauvelt, Richard Langley, J.‐P. Lacour, Darryl Toth, Vivian Laquer, Stefan Beissert, Andreas Wollenberg, Pedro Herranz, Andrew Pink, Ketty Peris, Stine Fangel, Le Gjerum, Joshua Corriveau, Hidehisa Saeki, Richard B. Warren, Eric L. Simpson, Kristian Reich

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study

    Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study 由 Amy S. Paller, Carsten Flohr, Lawrence F. Eichenfield, Alan D. Irvine, Jamie Weisman, Jennifer Soung, Ana Pinto Correia, Chitra R Natalie, Claudia Rodriguez Capriles, Evangeline Pierce, Sarah A. Reifeis, Renata Gontijo Lima, Clara Armengol Tubau, Vivian Laquer, Stephan Weidinger

    出版 2023
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis

    Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis 由 Eric L. Simpson, Melinda Gooderham, Andreas Wollenberg, Stephan Weidinger, April W. Armstrong, Jennifer Soung, Silvia Mariel Ferrucci, Renata Gontijo Lima, Michael M. Witte, Wen Xu, Hany Elmaraghy, Chitra R Natalie, Evangeline Pierce, Andrew Blauvelt, Abel Jarell, Neil S. Sadick, Howard Sofen, Paul W Wallace, Jose M Carpio, David Greenstein, Angela Moore, Jose M Mendez, Scott Guenthner, Wendy McFalda, Vivian Laquer, Seth Forman, Todd Schlesinger, Andrew Blauvelt, Jeffrey Crowley, Ricardo Tan, Francis J Averill, Rosalyn Elizabeth George, Eddie Armas, Benjamin Lockshin, Jennifer Soung, Walter K. Nahm, Alison A Ehrlich, Sunil Dhawan, Eric L. Simpson, Steve Sitar, Jerry Bagel, Phoebe Rich, Bruce Torkan, David F Fivenson, Jamie Weisman, Melody Lynn Stone, April W. Armstrong, Mirwais Saifi, Brad Glick, Melinda Gooderham, Isaiah Day, Lorne Albrecht, Marni Wiseman, David Gratton, Chi-ho Hong, Bernadetta Majorek‐Olechowska, Adam Reich, Beata Kręcisz, Irena Walecka-Herniczek, Jolanta Węgłowska, Beata Bergler‐Czop, Boguslawa Cimoszko, Kamila Padlewska, Maria Czubek, Andreas Pinter, Kristian Reich, Thomas Wildfeuer, Roland Aschoff

    出版 2023
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis

    Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis 由 Amy S. Paller, Marieke M.B. Seyger, Gabriel A. Magariños, Andreas Pinter, Jennifer Clay Cather, Claudia Rodriguez-Capriles, Danting Zhu, Najwa Somani, Alyssa Garrelts, Kim Papp, Gabriel A. Magariños, Ricardo Galimberti, Diego Oscar Viola, Paula Carolina Luna, Charles Lynde, Danielle Marcoux, Vimal H. Prajapati, Ajith Cy, Petr Arenberger, Stanislava Polášková, Hans Buckova, Jirina Bartonová, Petra Cetkovská, Jana Hercogová, J.‐P. Lacour, Alice Phan, Michael Sticherling, Petra Staubach, Margrit Simon, Andreas Pinter, Nina Magnolo, Piroska Dosa, Judit Noll, Éva Remenyik, Lajos Kemény, Noémi Bakos, Claudia Bernabe del Rio, Mirna Toledo‐Bahena, Minerva Gómez Flores, Zamira Barragan Estudillo, Marieke M.B. Seyger, Jolanta Węgłowska, Elżbieta Szymańska, Andrzej Kaszuba, Nikolay N. Murashkin, Asuncion Vicente Villa, R Laguna, R. Rivera, Jerry Bagel, John Browning, Michael Bukhalo, Jennifer Clay Cather, Alma Cruz Santana, Boni E. Elewski, Seth Forman, José González-Chávez, Scott Gottlieb, Holly Hake Harris, Jessica Kaffenberger, Pearl Kwong, Sabre Leitenberger, Aída Lugo‐Somolinos, A. Yasmine Kirkorian, Kari A. Martin, Amy S. Paller, David M. Pariser, Phoebe Rich, Adena E. Rosenblatt, Lucia Seminario‐Vidal, Elaine C. Siegfried, Jeffrey B. Travers, Pedro Vendrell-Benito, Jamie Weisman, Lara Wine Lee, Matthew Zook, Samuel Sanches-Rivera, Vivian Laquer

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: